1ZL Stock Overview
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Zai Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.80 |
| 52 Week High | US$31.80 |
| 52 Week Low | US$12.40 |
| Beta | 1.02 |
| 1 Month Change | 6.61% |
| 3 Month Change | -5.15% |
| 1 Year Change | 49.13% |
| 3 Year Change | -48.19% |
| 5 Year Change | -55.52% |
| Change since IPO | 7.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1ZL | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.4% | -0.5% | 2.1% |
| 1Y | 49.1% | -6.5% | 16.5% |
Return vs Industry: 1ZL exceeded the German Biotechs industry which returned -5.6% over the past year.
Return vs Market: 1ZL exceeded the German Market which returned 16.7% over the past year.
Price Volatility
| 1ZL volatility | |
|---|---|
| 1ZL Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1ZL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1ZL's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 2,175 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Zai Lab Limited Fundamentals Summary
| 1ZL fundamental statistics | |
|---|---|
| Market cap | €2.84b |
| Earnings (TTM) | -€260.58m |
| Revenue (TTM) | €342.27m |
8.6x
P/S Ratio-11.2x
P/E RatioIs 1ZL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1ZL income statement (TTM) | |
|---|---|
| Revenue | US$355.75m |
| Cost of Revenue | US$395.21m |
| Gross Profit | -US$39.46m |
| Other Expenses | US$231.39m |
| Earnings | -US$270.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -2.49 |
| Gross Margin | -11.09% |
| Net Profit Margin | -76.13% |
| Debt/Equity Ratio | 16.9% |
How did 1ZL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/12 03:46 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zai Lab Limited is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Meng | BOCI Research Ltd. |
| Wai Chak Yuen | BOCI Research Ltd. |
| Linda Lu | BOCI Research Ltd. |